Silo Pharma, Inc. (SILO) Stock Score, Valuation & Financial Research
Silo Pharma, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 28/100.
Quick answer for SILO
Silo Pharma, Inc. currently has a Wall Street Score of 28/100. The stored market price is $2.1. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is +0.4 points. These figures are a research snapshot, not a buy or sell recommendation.
What Silo Pharma, Inc. does
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homi
SILO financial snapshot
- Wall Street Score:
- 28/100
- Current price:
- $2.1
- Market capitalization:
- $2.4M
- Revenue:
- $54K
- Net income:
- $-4.5M
- Free cash flow:
- $-4.7M
- Cash:
- $3.3M
- Total debt:
- $0
- EPS:
- -5.35
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is -0.2%.
- Free cash flow is $-4.7M, showing cash burn in the current stored period.
- The balance sheet shows $3.3M of cash versus $0 of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.4 points: SILO increased 0.4 points because Capital improved by 6 points.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-13.
How to research SILO
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.